Drug Trial Radar · NCT06708845
US Zamto-cel Autoimmune Diseases
Last checked: Nov 20, 2026Latest source record: Jun 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Jul 2026
Primary completion
Jan 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Miltenyi Biomedicine GmbHIndustry
- Sponsor type
- Industry
- First posted
- Nov 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard therapy.
Conditions
- Lupus Nephritis
- Systemic Lupus Erythematosus
- Systemic Sclerosis (SSc)
- Diffuse Cutaneous Systemic Sclerosis
Interventions
zamtocabtagene autoleucelBiological
chimeric antigen receptor T-cell (CAR-T) therapy
CyclophosphamideDrug
Lymphodepleting chemotherapy
FludarabineDrug
Lymphodepleting chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence and severity of adverse events (AEs), adverse events of special interest (AESIs), and serious adverse events (SAEs)Time frame: From enrollment through study completion 12 months post zamto-cel infusion
- The proportion of subjects with dose-limiting toxicities (DLTs) up to Day 28 and determination of recommended Phase 2 dose (RP2D)Time frame: From enrollment through Day 28 post zamto-cel infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.